Search results
Germany's Merck, Korean science institute set up R&D partnership
dpa international via Yahoo News· 4 days agoGerman science and technology major Merck and the Korea Advanced Institute of Science and Technology...
Merck nears $1.3 billion cash deal for eye-drug company EyeBio, WSJ reports
Reuters via Yahoo Finance· 6 days agoMerck has said it's in the market for deals of up to around $15 billion as it plans ways to deal...
Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?
Zacks via Yahoo Finance· 8 hours agoThis ETF has heaviest allocation in the Healthcare sector--about 100% of the portfolio. Looking at...
Merck nears $1.3 billion cash deal for eye-drug company EyeBio, WSJ reports By Reuters
Investing.com· 6 days agoMerck did not immediately respond to Reuters' request for a comment, while Eyebiotech declined to...
MRK stock rated a Sell by Societe Generale – Knox Daily
Knox Daily· 6 days agoMerck & Co Inc’s filing revealed that its 10% Owner Merck & Co., Inc. acquired Company’s shares for reported $492.14 million on Mar 11 ’24. In the deal ...
Merck acquires EyeBio in up to $3B deal By Proactive Investors
Investing.com· 5 days agoMerck & Co Inc (NYSE:MRK, ETR:6MK) announced it is acquiring Eyebio, a privately held...
Merck's Multi-Billion Cancer Drug Keytruda Aces Late-Stage Breast Cancer Study (UPDATED)
Benzinga· 6 days agoEditor’s Note: The title of the story is updated to correct the reference to ‘Breast’ cancer instead...
Merck’s KEYTRUDA shows survival benefits in Phase III TNBC trial
Clinical Trials Arena via Yahoo Finance· 5 days agoMerck has reported that its Phase III KEYNOTE-522 clinical trial of KEYTRUDA to treat high-risk,...
Merck to buy eye-focused drug developer EyeBio for as much as $3 bln
Reuters· 5 days agoThe deal is the latest in a string of recent acquisitions by Merck to reduce its reliance on...
Merck to buy eye-focused drug developer EyeBio for as much as $3 billion
CNBC· 5 days agoIt agreed to pay $1.3 billion in cash and another $1.7 billion in future milestone-based payments...